Menu

Less pain. Fewer side effects.

An alternate route of drug delivery

Targeted drug delivery overview

Intrathecal drug delivery enables patients to experience pain relief using a fraction of an oral medication dose,1–3 which can help to minimize the uncomfortable and sometimes intolerable side effects (e.g., drowsiness, dizziness, nausea, vomiting and constipation) that often accompany pain medication taken orally.2–5

The SynchroMed™ III intrathecal pump and implanted catheter releases prescribed amounts of pain medication directly into the intrathecal space, interrupting pain pathways at the source. Unlike oral medications that must be absorbed systemically and cross the blood-brain barrier to reach pain signals, targeted drug delivery interrupts pain pathways at their source in the cerebrospinal fluid and spinal cord. An implanted, programmable pump and catheter release prescribed amounts of pain medication directly into the intrathecal space.

The SynchroMed™ Clinician Programmer provides a simple, guided workflow approach to programming SynchroMed™ implantable pumps and the myPTM™ Personal Therapy Manager works with the SynchroMed™ pump to help alleviate unpredictable pain by enabling on-demand intrathecal boluses.

Meet SynchroMed™ III
SynchroMed™ III is an implantable targeted drug infusion system that helps manage chronic pain, cancer pain, and severe spasticity.
This is an image of a female patient sitting down on an exam bed next to a male physician in an exam room in discussion.


Intrathecal drug delivery enables patients to experience pain relief using a fraction of an oral medication dose.1–3

Helping eliminate systemic opioids

The Control Workflow™ for targeted drug delivery (TDD) is an approach to help eliminate systemic opioids and provide effective pain relief. The purpose of this workflow is to provide a treatment option for chronic pain using low-dose TDD. Patients should receive appropriate pain treatment based on careful consideration of benefits and risks of treatment options.

TDD has demonstrated a substantial reduction in the amount of drug required to effectively manage chronic pain. By having an outlined workflow, we are hoping to reduce perceived barriers to the TDD therapy.3

Download the workflow (open in new window)

Empower patients to alleviate pain

SynchroMed™ III pump

The SynchroMed™ III is an implantable drug delivery system that helps manage chronic pain, cancer pain, and severe spasticity. Learn more about each of the indications below.

 

Chronic pain

See an effective treatment option for patients who suffer from intractable pain.

Learn how

Cancer pain

When oral medications aren’t enough, intrathecal opioids may offer relief.

Learn how

Severe spasticity

Learn how TDD can be effective for patients with severe spasticity.

Learn how

 

 

  1. Grider JS, Harned ME, Etscheidt MA. Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain. Pain Physician. 2011;14:343–351.
  2. Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012;13:1304–1313.
  3. Ruan X. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician. 2007;10:357–366.
  4. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;20(1):CD006605. 
  5. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20:4040–4049.